Lv64
1740 积分 2024-10-25 加入
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
13天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
13天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
13天前
已完结
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
13天前
已完结
The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: A meta-analysis
14天前
已完结
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
14天前
已完结
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial
1个月前
已完结
Nonoperative Management of Mismatch Repair–Deficient Tumors
2个月前
已完结
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
2个月前
已完结
Harnessing the biology of regulatory T cells to treat disease
2个月前
已完结
皖公网安备34019202002308
